Efficacy and safety of rocatinlimab for the treatment of moderate-to-severe atopic dermatitis in ROCKET-IGNITE and ROCKET-HORIZON: two global, double-blind, placebo-controlled, randomised phase 3 clinical trials

作者：Emma Guttman‐Yassky, Kenji Kabashima, Margitta Worm, Paula Carolina Luna, Hwanhee Hong, Raj Chovatiya, Jonathan A. Bernstein, Johannes S. Kern, Benjamin D. Ehst, Nina Magnolo, Pedro Herranz, Linda Stein Gold, Howard Sofen, Andrew Pink, Ehsanollah Esfandiari, Takahiro Arai, Yiping Yang, Rebecca Shi, Carolina Barragan, Greg Kricorian, Liat Schwartz-Sagi, Robert Bissonnette · 发表于：The Lancet · 年份：2025 · DOI：10.1016/s0140-6736(25)01865-3 · 被引用次数：14 · 研究领域：Dermatology and Skin Diseases、Psoriasis: Treatment and Pathogenesis、Urticaria and Related Conditions